Effects of treatment with rhEPO on quality of life in anemic cancer patients

  • S. S. Yip
  • Peter G. Harper


Anemia is one of the multitude of problems that cancer patients may expe­rience. Under normal conditions, erythropoietin, a glycoprotein hormone produced in the kidney in response to anemia, stimulates the production of red blood cells, however, in cancer patients the erythropoietin response may be diminished. Indeed, the endogenous levels of erythropoietin in cancer patients with anemia is significantly lower than in cancer patients who expe­rience a similar degree of anemia caused by iron deficiency [31]. In addition, the erythropoietin response in cancer patients undergoing chemotherapy treatment is compromised [31]. Logically then, the adjustment of erythro­poietin levels is one approach to alleviating anemia.


Recombinant Human Erythropoietin Anemic Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abels R (1993) Erythropoietin for anemia in cancer patients. Eur J Cancer 29A (Suppl 2): S2 - S8CrossRefGoogle Scholar
  2. 2.
    Barrett-Lee PJ, Bailey NP, O’Brien ME, Wager E (2000) Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82: 93–97PubMedCrossRefGoogle Scholar
  3. 3.
    Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12: 1058–1062PubMedGoogle Scholar
  4. 4.
    Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: 801–806PubMedCrossRefGoogle Scholar
  5. 5.
    Cassileth BR, Lusk EJ, Bodenheimer BJ, Farber JM, Jochimsen P, Morrin-Taylor B (1985) Chemotherapeutic toxicity-the relationship between patients’ pretreatment expectations and posttreatment results. Am J Clin Oncol 8: 419–425PubMedCrossRefGoogle Scholar
  6. 6.
    Cazzola M, Mercuriali F, Brugnara C (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood 89: 4248–4267PubMedGoogle Scholar
  7. 7.
    Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 86: 4446–4453PubMedGoogle Scholar
  8. 8.
    Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25 (Suppl 7): 43–46PubMedGoogle Scholar
  9. 9.
    Cleeland CS, Demetri GD, Glaspy J, Cella DF, Portenoy RK, Cremieux PY, Itri LM (1999) Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis. In: Proceedings of the American Society of Clinical Oncology, Atlanta, Georgia. Atlanta, Georgia. 18: 574a Abstr 2215Google Scholar
  10. 10.
    Coiffier B (2001) Manuscript in preparationGoogle Scholar
  11. 11.
    Curt GA, Breitbart W, Cella DF, Groopman JE, Horning SJ, Itri L, Johnson DH, Miaskowski C, Portenoy RK, Scherr S, Vogelzang NJ (1999) Impact of cancer-related fatigue on the lives of patients. In: Proceedings of the American Society of Clinical Oncology, Atlanta, Georgia. ASCO, Alexandria. 18: 573a Abstr 2214Google Scholar
  12. 12.
    Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412–3425Google Scholar
  13. 13.
    Ferrell BR, Dow KH, Grant M (1995) Measurement of the quality of life in cancer survivors. Quality of Life Research 4: 523–531PubMedCrossRefGoogle Scholar
  14. 14.
    Gabrilove JL, Einhorn LH, Livingston RB, Winer E, Cleeland CS (1999) Once-weekly dosing of epoietin alfa is similar to three-times-weekly dosing in increasing hemoglobin and quality of life. In: Proceedings of the American Society of Clinical Oncology, Atlanta, Georgia. ASCO, Alexandria. 18: 574a Abstr 2216Google Scholar
  15. 15.
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218–1234PubMedGoogle Scholar
  16. 16.
    Glaspy JA (2000) Hematologic supportive care of the critically ill cancer patient. Semin Oncol 27: 375–383PubMedGoogle Scholar
  17. 17.
    Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO (1994) Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 73: 556–562PubMedCrossRefGoogle Scholar
  18. 18.
    Glimelius B, Linne T, Hoffman K, Larsson L, Svensson JH, Nasman P, Svensson B, Helmers C (1998) Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16: 434–440PubMedGoogle Scholar
  19. 19.
    Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–1634PubMedCrossRefGoogle Scholar
  20. 20.
    Henry DH, Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 21 (Suppl 3): 21–28PubMedGoogle Scholar
  21. 21.
    Huskisson EC (1974) Measurement of pain. Lancet 2: 1127–1131PubMedCrossRefGoogle Scholar
  22. 22.
    Huskisson EC (1982) Measurement of pain. J Rheumatol 9: 768–769PubMedGoogle Scholar
  23. 23.
    Irvine D, Vincent L, Graydon JE, Bubela N, Thompson L (1994) The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nursing 17: 367–378PubMedCrossRefGoogle Scholar
  24. 24.
    Irvine DM, Vincent L, Bubela N, Thompson L, Graydon J (1991) A critical appraisal of the research literature investigating fatigue in the individual with cancer. Cancer Nursing 14: 188–199PubMedGoogle Scholar
  25. 25.
    Itri LM (2000) Optimal hemoglobin levels for cancer patients. Semin Oncol 27 (Suppl 4): 12–15PubMedGoogle Scholar
  26. 26.
    Kazis LE, Anderson JJ, Meenan RF (1989) Effect sizes for interpreting changes in health status. Medical Care 27: S178 - S189PubMedCrossRefGoogle Scholar
  27. 27.
    Littlewood TJ, Bajetta E, Cella D (1999) Efficacy and quality of life outcomes of epoetin alfa in a double-blind, placebo-controlled multicenter study of cancer patients receiving non-platinum containing chemotherapy. In: Proceedings of the American Society of Clinical Oncology, Atlanta, Georgia. ASCO, Alexandria. 18: 574a Abstr 2217Google Scholar
  28. 28.
    Littlewood TJ, Rapoport B, Bajetta E, Nortier J (2000) Possible relationship of hemoglobin levels with survival in anemic cancer patients receiving chemotherapy. In: Proceedings of the American Society of Clinical Oncology, New Orleans, Louisiana. ASCO, Alexandria. 19: 605a Abstr 2381Google Scholar
  29. 29.
    Maxwell C (1978) Sensitivity and accuracy of the visual analogue scale: a psycho-physical classroom experiment. Br J Clin Pharmacol 6: 15–24PubMedGoogle Scholar
  30. 30.
    McCormack HM, Home DJ, Sheather S (1988) Clinical applications of visual analogue scales: a critical review. Psychol Med 18: 1007–1019PubMedCrossRefGoogle Scholar
  31. 31.
    Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322: 1689–1692PubMedCrossRefGoogle Scholar
  32. 32.
    Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, NetterPinon J, Tubiana-Mathieu N, Zwierzina H (1998) Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9: 255–260PubMedCrossRefGoogle Scholar
  33. 33.
    Österborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma—a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood 87: 2675–2682PubMedGoogle Scholar
  34. 34.
    Österborg A, Brandberg Y, Molostova V, Iosova V, Abdulkadyrov K, Hedenus M, Messinger D (2002) Randomized, double-blind, placebo-controlled trial of the effect of epoetin beta on quality of life of patients with hematological malignancies. J Clin Oncol 20: in pressGoogle Scholar
  35. 35.
    Portenoy RK, Itri LM (1999) Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4: 1–10PubMedGoogle Scholar
  36. 36.
    Ream E, Richardson A (1997) Fatigue in patients with cancer and chronic obstructive airways disease: a phenomenological enquiry. Int J Nurs Stud 34: 44–53PubMedCrossRefGoogle Scholar
  37. 37.
    Scott J, Huskisson EC (1976) Graphic representation of pain. Pain 2: 175–184PubMedCrossRefGoogle Scholar
  38. 38.
    Scott J, Huskisson EC (1979) Vertical or horizontal visual analogue scales. Ann Rheum Dis 38: 560PubMedCrossRefGoogle Scholar
  39. 39.
    Stone P, Hardy J, Huddart R, A’Hern R, Richards M (2000) Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 36: 1134–1141PubMedCrossRefGoogle Scholar
  40. 40.
    Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N (2000) Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Ann Oncol 11: 971–975PubMedCrossRefGoogle Scholar
  41. 41.
    ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristensen GB, van Tinteren H, Ehmer B (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15: 174–182PubMedCrossRefGoogle Scholar
  42. 42.
    ten Bokkel-Huinink W (1996) Controlled multicentre study of influence of two different doses of subcutaneous rhEPO on the development of anemia and transfusion dependency in patients with ovarian carcinoma treated with platinum based chemotherapy. In: Smyth JF, Boogaerts MA, Ehmer BRM (eds) rhErythropoietin in Cancer Supportive Treatment. Marcel Dekker, New York, NY, pp 99–111Google Scholar
  43. 43.
    Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 (Suppl 2): 4–12PubMedGoogle Scholar
  44. 44.
    Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy ( FACT) measurement system. J Pain Symptom Manage 13: 63–74PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  1. 1.Medical OncologyGuy’s HospitalLondonUK

Personalised recommendations